Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.

Abstract

Objectives: The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS).Methods: This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group).Results: After excluding 11 miscarriages with abnormal embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates of patients treated with danaparoid and UFH were similar and tended to be higher than that of patients treated with LDA, respectively (OR 4.0, 95% confidence interval 0.72-22.22 and 5.15, 1.33-20.00). No patient given danaparoid and one patient with UFH developed heparin-induced thrombocytopenia which resulted in a stillbirth. Another patient with UFH suffered a lumbar compression fracture.Conclusion: Danaparoid is effective for improving the live birth rate and is safe for patients with oAPS.

• Authors: Hiroyuki Yoshihara, Mayumi Sugiura-Ogasawara, Tamao Kitaori, Kinue Katano, Yasuhiko Ozaki
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 30 Issue 2 Pg. 332-337 (Mar 2020) ISSN: 1439-7609 [Electronic] England
• PMID: 30924705 (Publication Type: Journal Article)

Chemical References

• Fibrinolytic Agents
• Dermatan Sulfate
• Chondroitin Sulfates
• Heparitin Sulfate
• danaparoid

Topics

• Adult
• Antiphospholipid Syndrome (drug therapy)
• Chondroitin Sulfates (administration & dosage, adverse effects, therapeutic use)
• Dermatan Sulfate (administration & dosage, adverse effects, therapeutic use)
• Female
• Fibrinolytic Agents (administration & dosage, adverse effects, therapeutic use)
• Heparitin Sulfate (administration & dosage, adverse effects, therapeutic use)
• Humans
• Pregnancy
• Pregnancy Complications (drug therapy)
• Pregnancy Outcome